News & Updates

Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.

Acid suppression (AS) medications, such as proton pump inhibitors (PPIs) and histamine type-2 receptor antagonists (H2RAs), weaken the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in nonsmall cell lung cancer (NSCLC), resulting in worse survival outcomes, according to a recent Singapore meta-analysis.

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.